Patents Examined by Ekaterina Poliakova-Georgantas
  • DNA aptamer binding to cancer cell
    Patent number: 10837964
    Abstract: The purpose of the present invention is to provide an aptamer to a cancer cell, said aptamer being superior to conventional aptamers in binding ability, specificity, and/or stability. To solve this problem, provided is a DNA aptamer binding to a cancer cell, said DNA aptamer containing an artificial base(s).
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: November 17, 2020
    Assignee: Agency for Science, Technology and Research
    Inventors: Kazunobu Futami, Ichiro Hirao, Michiko Hirao
  • Oligonucleotides for reduction of PD-L1 expression
    Patent number: 10829555
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: November 10, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
  • Ribonucleic acids with 4?-thio-modified nucleotides and related methods
    Patent number: 10822368
    Abstract: Disclosed are messenger RNA molecules and related compositions incorporating a 4?-thio modification in the furanose ring of at least one nucleotide residue, and methods of using these mRNAs to produce an encoded therapeutic protein in vivo and to treat or prevent diseases or disorders. In certain embodiments, the 4?-thio modified mRNA provides for enhanced stability and/or reduced immunogenicity in in vivo therapies.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: November 3, 2020
    Assignee: Translate Bio, Inc.
    Inventors: Frank DeRosa, Michael Heartlein
  • Modulation of alpha synuclein expression
    Patent number: 10815480
    Abstract: Disclosed herein are antisense compounds and methods for decreasing alpha-synuclein mRNA and protein expression. Also disclosed herein are methods for treating, preventing, and ameliorating neurodegenerative diseases in an individual in need thereof.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: October 27, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Inhibition of lncRNA HOTAIR and related materials and methods
    Patent number: 10801024
    Abstract: Embodiments disclosed herein concern compositions and methods for treating a condition characterized by overexpression of long non-coding RNA HOTAIR. In certain embodiments, synthetic polynucleotide analogs capable of hybridizing with a target sequence domain of HOTAIR are provided. The synthetic polynucleotide analogs can be formulated into a pharmaceutical composition for treating a subject having or at risk of having a condition characterized by HOTAIR overexpression. In certain embodiments, the pharmaceutical composition can resensitize a subject to a chemotherapeutic agent. Other embodiments concern uses for HOTAIR-targeting synthetic polynucleotide analogs, including methods for determining HOTAIR expression in a sample.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: October 13, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Ali Rayet Ozes, Kenneth P. Nephew
  • Compositions for controlling mites in bees
    Patent number: 10801028
    Abstract: An isolated nucleic acid agent is disclosed comprising a nucleic acid sequence which downregulates expression of a gene product of a Varroa destructor mite. Compositions comprising same and uses thereof are also disclosed.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: October 13, 2020
    Assignees: BEEOLOGICS INC., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Ilan Sela, Sharoni Shafir, Eyal Maori, Yael Garbian, Eyal Ben-Chanoch, Gal Yarden, Haim Kalev
  • Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof
    Patent number: 10781449
    Abstract: The present application relates to nucleic acid compounds, compositions comprising same and methods of use thereof for treatment of various diseases, disorders and conditions. The compounds are preferably chemically synthesized and modified double-stranded nucleic acid molecules which down regulate expression of a p53 gene.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: September 22, 2020
    Assignee: QUARK PHARMACEUTICALS, INC.
    Inventors: Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett
  • Programmed cargo release using nucleic acid-stabilized micelles
    Patent number: 10780051
    Abstract: Methods and compositions for serum-stabilizing micelles for drug delivery or imaging agent delivery are provided, as well as methods and compositions to enhance micelle-mediated drug delivery. This invention provides a process for synthesizing a lipid micelle comprising one or more lipid-oligonucleotide conjugate molecules, the process comprising contacting an amount of lipid molecules with an amount of lipid-oligonucleotide conjugate molecules sufficient to create a lipid micelle comprising lipid-oligonucleotide conjugate molecules.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: September 22, 2020
    Assignee: Albert Einstein College of Medicine
    Inventors: Samantha E. Wilner, Matthew Levy
  • DNA aptamer that binds to vWF
    Patent number: 10760083
    Abstract: The purpose of the present invention is to provide an aptamer for vWF, which is superior in a binding ability, a dissociation rate, and/or stability to the conventional nucleic acid aptamers. The present invention can solve the problem by a DNA aptamer which contains artificial nucleotides and binds to vWF.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: September 1, 2020
    Assignee: TAGCyx Biotechnologies Inc.
    Inventors: Ichiro Hirao, Michiko Hirao, Kenichiro Matsunaga
  • ?-amylase-binding nucleic acid molecule and use thereof
    Patent number: 10760084
    Abstract: The present invention provides a novel nucleic acid molecule that can be used for detection of ?-amylase. The ?-amylase-binding nucleic acid molecule of the present invention is characterized in that it binds to ?-amylase with a dissociation constant of 17 nM or less, and preferably includes a polynucleotide consisting of any of base sequences of SEQ ID NOs: 1 to 22, for example. According to the nucleic acid molecule of the present invention, it is possible to detect ?-amylase in saliva.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: September 1, 2020
    Assignees: NEC Solution Innovators, Ltd., Gunma University
    Inventors: Hirotaka Minagawa, Katsunori Horii, Jou Akitomi, Naoto Kaneko, Ikuo Shiratori, Iwao Waga, Masayasu Kuwahara
  • Inhibition of ferrochelatase as an antiangiogenic therapy
    Patent number: 10752901
    Abstract: Methods for treating angiogenesis-mediated diseases are disclosed. More particularly, the present disclosure relates to methods of inhibiting ferrochelatase as an antiangiogenic therapy.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: August 25, 2020
    Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Timothy Corson, Halesha Basavarajappa
  • Oligonucleotides for reduction of PD-L1 expression
    Patent number: 10745480
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: August 18, 2020
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
  • Aptamer against insulin receptor and pharmaceutical compostion containing the same
    Patent number: 10724039
    Abstract: The present disclosure relates to a DNA aptamer which specifically binds to an insulin receptor, and a composition for treating diabetes and a composition for diagnosing diabetes which contain the same as an active ingredient, and the aptamer is characterized by being able to treat and diagnose diabetes more effectively than side effects caused by insulin such as increased incidence of cancer and atherosclerosis by having a different binding mechanism from existing insulin.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: July 28, 2020
    Assignees: Posco, Postech Academy-Industry Foundation
    Inventors: Sung Ho Ryu, Na-Oh Yunn, Jong Hun Im, Ara Koh, Eun Ju Oh, Sehoon Park, Jiyoun Lee, Sung Key Jang, Seungmin Han, Youndong Kim
  • Composition for delivery of genetic material
    Patent number: 10704047
    Abstract: The present invention relates to exosomes, loaded with genetic material and methods of producing them and to the use of such exosomes for delivering genetic material in vivo, in particular the use of such exosomes in methods of gene therapy or gene silencing.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: July 7, 2020
    Assignee: Oxford University Innovation Limited
    Inventors: Yiqi Seow, Lydia Alvarez, Matthew Wood
  • Targeting fibroblast invasion for pulmonary fibrosis
    Patent number: 10705074
    Abstract: The described invention provides a method for identifying a therapeutic compound effective to reduce invasiveness of fibroblasts characterized by a highly invasive phenotype obtained from a subject with idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: July 7, 2020
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Paul W. Noble, Dianhua Jiang, Carol Jiurong Liang
  • Pharmaceutical composition for treating and/or preventing cancer
    Patent number: 10689649
    Abstract: The present invention provides a novel pharmaceutical composition for treating and/or preventing a cancer comprising, as an active ingredient, a polynucleotide derived from various miRNAs associated with cancer, a combination drug of the pharmaceutical composition and another antitumor agent, and a method for treating or preventing a cancer in a subject having the cancer using the pharmaceutical composition or the combination drug. The present invention relates to a pharmaceutical composition for treating and/or preventing a cancer comprising, as an active ingredient, a polynucleotide comprising the nucleotide sequence as set forth in SEQ ID NO: 1 or 2 (wherein when at least a part of the polynucleotide is DNA, uracil in a region corresponding to the DNA in the nucleotide sequence is replaced with thymine).
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: June 23, 2020
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Atsuko Miyano, Hiroko Sudo, Aiko Takayama, Taiga Arai
  • CD117 ligand-drug conjugates for targeted cancer therapy
    Patent number: 10683506
    Abstract: Disclosed are compositions and methods relating to nucleic acid aptamers that specifically target CD117 protein and also selective binding to CD117-expressing cells. The ligand-drug conjugates specifically target CD117-expressing cells and subsequently internalize into the cells, leading apoptosis, growth inhibition, and death of cells of interest and no off-target toxicity to CD117-negative normal cells.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: June 16, 2020
    Inventor: Youli Zu
  • Methods of treating fragile X syndrome and related disorders
    Patent number: 10682397
    Abstract: Disclosed herein are novel methodologies of treating fragile X syndrome and related disorders by inhibiting mGlu5-relevant signaling pathways via the reduction of ?-arrestin2 protein levels or the diminution of mGlu5 and ?-arrestin2 protein interactions.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 16, 2020
    Assignees: Massachusetts Institute of Technology, Duke University
    Inventors: Benjamin David Auerbach, Mark Firman Bear, Laura Jane Stoppel, Robert J. Lefkowitz
  • Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
    Patent number: 10676742
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing transth:yretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: June 9, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Functional ligands to THC
    Patent number: 10676781
    Abstract: The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules, such as tetrahydrocannabinol (THC).
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: June 9, 2020
    Assignee: Base Pair Biotechnologies, Inc.
    Inventor: George W. Jackson